SCHEMBL6180945

SCHEMBL6180945

NC(=O)[N+]1(c2ccccc2Cl)CCc2cc3ccnc(N4CCNCC4)c3cc21

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 8/20 0.46
HTR1D P28221 8/20 0.46
HTR1B P28222 8/20 0.46
HTR2C P28335 2/20 0.45
PRKD1 Q15139 2/20 0.40
PRKD2 Q9BZL6 2/20 0.40
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C19 P33261 2/20 0.39
LMNA P02545 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
HTR6 P50406 3/20 0.38
MEN1 O00255 1/20 0.35
CYP2D6 P10635 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6180948 0.71 HTR1A (0.60) HTR1AHTR1DHTR1BHTR2CCYP1A2
SCHEMBL16647211 0.70 HTR2C (0.58) HTR1AHTR1DHTR1BHTR2CCYP1A2
SCHEMBL6179304 0.66 HTR1A (0.64) HTR1AHTR1DHTR1BHTR2CMAPT
SCHEMBL6179764 0.66 HTR2C (0.51) HTR1AHTR1DHTR1BHTR2CHTR6
SCHEMBL13170117 0.65 HTR2C (0.64) HTR2CHTR6
SCHEMBL3683092 0.65 HTR2C (0.64) HTR1AHTR2CPRKD1HTR6
SCHEMBL3676460 0.65 HTR2C (0.64) HTR1AHTR2CPRKD1LMNAHTR6
SCHEMBL2076366 0.65 HTR2C (1.00) HTR1AHTR1DHTR1BHTR2CCYP1A2
SCHEMBL30040877 0.65 HTR2C (1.00) HTR1AHTR1DHTR1BHTR2CCYP1A2
Hydrochloric Acid SCHEMBL31587078 0.64 HTR2C (0.62) HTR1AHTR2CPRKD1HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050239797-A1 Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity SMITHKLINE BEECHAM, PLC 2005-10-27 US disclosed
EP-1228043-B1 ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY SMITHKLINE BEECHAM PLC (GB) 2005-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239797-A1 Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity HTR1B, HTR1A, HTR1D HTR1A 2/4885HTR1D 3/4885HTR1B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.